Literature DB >> 29144548

Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome.

Thozhukat Sathyapalan1, Ahmed Al-Qaissi1, Eric S Kilpatrick2, Soha R Dargham3, Stephen L Atkin4.   

Abstract

OBJECTIVE: Anti-Müllerian hormone (AMH) is derived from the small antral follicles, and an elevated level has been suggested to add value to the Rotterdam criteria for the diagnosis of PCOS in cases of diagnostic uncertainty. Therefore, the role of AMH in the classical phenotype of PCOS was defined within a Caucasian population.
DESIGN: This was a cross-sectional study. PATIENTS: Sixty Five women without PCOS and 110 women with PCOS fulfilling all 3 diagnostic Rotterdam criteria. MEASUREMENTS: The main outcomes were the utility of serum AMH for the diagnosis of PCOS and its relationship to the metabolic parameters.
RESULTS: Anti-Müllerian hormone was increased in PCOS compared to controls (P < .001). Areas under the receiver operator curve showed AMH to be predictive of PCOS (0.76) using a cut-off AMH of 46 pmol/L, which is derived from the 95th percentile of the controls that gave a 41% sensitivity and 86% specificity; an AMH cut-off of 35 pmol/L gave a 55% sensitivity and 79% specificity. Age- and BMI-adjusted multiple logistic regression showed that AMH was more predictive of PCOS independently of either serum testosterone (T) (OR = 4.04; 95% CI 1.42-11.11; P = .007) or free androgen index (FAI) (OR = 3.90; 95% CI 1.40-10.83; P = .009).
CONCLUSION: Whilst an elevated AMH has poor sensitivity, it is fourfold more likely to be associated with a diagnosis of PCOS, and supplementary to biochemical parameters will make a positive diagnosis of PCOS in 22% of patients when neither serum testosterone nor FAI is elevated.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  androgen; anti-müllerian hormone; polycystic ovary syndrome; rotterdam criteria

Mesh:

Substances:

Year:  2017        PMID: 29144548     DOI: 10.1111/cen.13517

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?

Authors:  Abu Saleh Md Moin; Thozhukat Sathyapalan; Alexandra E Butler; Stephen L Atkin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

2.  Can we use serum Anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles.

Authors:  Hüseyin Aydoğmuş; Sefa Kelekçi; Ferhan Elmalı; Serpil Aydoğmuş
Journal:  Saudi Med J       Date:  2018-10       Impact factor: 1.484

3.  Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms.

Authors:  Nada Ahmed; Asma A Batarfi; Osama S Bajouh; Sherin Bakhashab
Journal:  Diagnostics (Basel)       Date:  2019-10-01

4.  Increased MicroRNA Levels in Women With Polycystic Ovarian Syndrome but Without Insulin Resistance: A Pilot Prospective Study.

Authors:  Alexandra E Butler; Vimal Ramachandran; Thomas Keith Cunningham; Rhiannon David; Nigel J Gooderham; Manasi Benurwar; Soha R Dargham; Shahina Hayat; Thozhukat Sathyapalan; S Hani Najafi-Shoushtari; Stephen L Atkin
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-30       Impact factor: 5.555

5.  Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome.

Authors:  Abu Saleh Md Moin; Thozhukat Sathyapalan; Ilhame Diboun; Mohamed A Elrayess; Alexandra E Butler; Stephen L Atkin
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.